AmpliPhi Adds Two Board Members
This article was originally published in Scrip
Executive Summary
AmpliPhi Biosciences Corp. has appointed Vijay B. Samant and Paul C. Grint to its board as non-executive directors. Samant is currently president and CEO of Vical, Inc and prior to this he held various positions at Merck & Co. He was CEO of the Merck Vaccine Division, vice president (VP) of vaccine operations, VP of business affairs and director of materials management. Samant also served on the board of various companies including Raptor Pharmaceuticals and BioMarin. Grint is president and CEO of Regulus Therapeutics Inc. and before this he was president of Cerexa Inc. Previously he served in senior management roles at Forest Research Institute, Pfizer and IDEC Pharmaceuticals.